Products/R&D Pipelines
Marketed Products
-
Telitacicept
Telitacicept is a first-in-class fusion protein independently developed by RemeGen, which targets both recombinant B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) .It is characterized by a rapid onset of action, a high response rate, and a managable safety profile.
more
-
Disitamab Vedotin
Disitamab vedotin is the first original antibody-drug conjugate (ADC) in China and is also the first ADC in China to receive dual recognition as a breakthrough therapy from both the US FDA and the Chinese National Medical Products Administration. It is a HER2-targeted antitumor drug. Based on its unique structural design, it demonstrates significant advantages in safety and efficacy.
more
Marketing Team
The company's specialized marketing teams in autoimmunity and oncology have increasingly matured, reaching a scale of over 1,400 individuals. The products have covered thousands of hospitals across most provinces in the country, benefiting over 100,000 patients, with cumulative sales exceeding 5 billion yuan. Sales of the drugs are large and continue to grow rapidly.
Product Pipeline
Currently, the company’s product pipeline has dozens of innovative drugs in the R&D and commercialization stages. In addition to two world-class new drugs, Telitacicept and Disitamab Vedotin, another dual-target VEGF/FGF innovative fusion protein product, RC28, with the potential to be the First-in-class has entered Phase 3 clinical study in the field of ophthalmic treatments. Four drugs are in Phase 1/2 clinical studies, and many drugs are in the IND preparation stage.
- ●Autoimmune
- ●Oncology
- ●Ophthalmology
- Pre-clinic
- IND
- Phase Ⅰ
- Phase Ⅱ
- Pivotal/Phase Ⅲ
- NDA
- Launched
Pipeline Tips
No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.
（+86）535-3573511
Official WeChat